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ABSTRACT 
CONTEXT AND OBJECTIVE: Although glucometers have not been validated for intensive care units, they are regularly used. The aim of this study was to 
compare and assess the accuracy and clinical agreement of arterial glucose concentration obtained using colorimetry (Agluc-lab), capillary (Cgluc-strip) and 
arterial (Agluc-strip) glucose concentration obtained using glucometry and central venous glucose concentration obtained using colorimetry (Vgluc-lab). 
DESIGN AND SETTING: Cross-sectional study in a university hospital.
METHOD: Forty patients with septic shock and stable individuals without infection were included. The correlations between measurements were assessed 
both in the full sample and in subgroups using noradrenalin and presenting signs of tissue hypoperfusion. 
RESULTS: Cgluc-strip showed the poorest correlation (r = 0.8289) and agreement (-9.87 ± 31.76). It exceeded the limits of acceptable variation of the 
Clinical and Laboratory Standards Institute in 23.7% of the cases, and was higher than Agluc-lab in 90% of the measurements. Agluc-strip showed the 
best correlation (r = 0.9406), with agreement of -6.75 ± 19.07 and significant variation in 7.9%. For Vgluc-lab, r = 0.8549, with agreement of -4.20 ± 
28.37 and significant variation in 15.7%. Significant variation was more frequent in patients on noradrenalin (36.4% versus 6.3%; P = 0.03) but not in 
the subgroup with hypoperfusion. There was discordance regarding clinical management in 25%, 22% and 15% of the cases for Cgluc-strip, Vgluc-lab 
and Agluc-strip, respectively. 
CONCLUSION: Cgluc-strip should be avoided, particularly if noradrenalin is being used. This method usually overestimates the true glucose levels and 
gives rise to management errors. 
CLINICAL TRIAL REGISTRATION: ACTRN12608000513314 (registered as an observational, cross-sectional study)
RESUMO
CONTEXTO E OBJETIVO: Apesar de glicosímetros não serem validados para unidades de terapia intensiva (UTI), seu uso é corriqueiro. O objetivo foi avaliar 
a acurácia e concordância clínica entre a glicemia arterial por colorimetria (glicA-lab), glicemias capilar (glicC-fita) e arterial (glicA-fita) por glicosimetria, 
e venosa central por colorimetria (glicV-lab). 
TIPO DE ESTUDO E LOCAL: Estudo transversal realizado em hospital universitário. 
MÉTODO: Foram incluídos 40 pacientes com choque séptico e indivíduos estáveis, sem infecção. A correlação entre medidas foi avaliada tanto na 
amostra global quanto nos subgrupos em uso de noradrenalina e com sinais de hipoperfusão tecidual. 
RESULTADOS: A glicC-fita mostrou pior correlação (r = 0,8289) e concordância (-9,87 ± 31,76). Esta superou os limites aceitáveis de variação do Clinical 
and Laboratory Standards Institute em 23,7% dos casos, sendo maior que a glicA-lab em 90% das vezes. A glicA-fita teve a melhor correlação (r = 
0,9406), com concordância de -6,75 ± 19,07 e variação significativa em 7,9%. Para a glicV-lab, obteve-se r = 0,8549, concordância de -4,20 ± 28,37 e 
variação significativa em 15,7%. Variação significativa foi mais frequente em pacientes com noradrenalina (36,4% versus 6,3%, P = 0,03), mas não nos 
com hipoperfusão. Houve discordância de conduta clínica em 25%, 22,5% e 15% dos casos para glicC-fita, glicV-lab e glicA-fita, respectivamente. 
CONCLUSÃO: O uso de glicC-fita deveria ser evitado, principalmente se há uso de noradrenalina. Geralmente, este método superestima a glicemia real 
e acarreta erros de conduta.
REGISTRO DO ENSAIO CLÍNICO: ACTRN12608000513314 (registrado como estudo observacional transversal)
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INTRODUCTION
Severe sepsis and septic shock are the main causes of death in in-
tensive care units. More than 750,000 cases of severe sepsis occur an-
nually in the United States, amounting to 215,000 deaths/year in that 
country.1 Impaired microcirculation plays a leading role in this set-
ting and, unless corrected, it can evolve to multiple organ dysfunc-
tion and death.2,3
Glucose homeostasis becomes modified in these patients, thereby 
resulting in insulin resistance, hyperinsulinemia and consequent hy-
perglycemia. This set of conditions is named stress diabetes, and it is 
a physiological response that ensures glucose supply to non-insulin-
dependent tissues such as hepatocytes, nerve cells and alveolar, en-
dothelial and immune system cells. Hyperglycemia is an independent 
predictor of adverse outcomes in cases of cardiovascular disease, neu-
rological disorders, respiratory, liver and gastrointestinal disease, ma-
lignancy, sepsis and surgical patients.4,5 Normoglycemia is related to 
lower morbidity and mortality because of improvements in systemic 
inflammatory processes and in immune, endothelial and mitochon-
drial dysfunctions.6-8 Normoglycemic patients are less susceptible to 
bloodstream infection, renal failure, anemia and transfusion, polyneu-
ropathy, hyperbilirubinemia and prolonged dependence on both me-
chanical ventilation and intensive care therapy.9,10 Additionally, glu-
cose control is cost-effective.11
Thus, although glucose control is a priority in treating critically 
ill patients, glucose monitoring can be quite challenging. Consider-
ing that many intensive care patients are unable to express signs and 
symptoms of hypoglycemia, frequent and accurate measurements are 
pivotal.12 Given the low cost, easy sampling and prompt results of glu-
cometers, capillary blood glucose levels are often determined using this 
method, although it has not been validated for intensive care patients.5 
Critically ill patients have multiple relevant conditions that can in-
terfere with measurements such as pH,13 partial pressure of oxygen,14 
hematocrit,15 blood glucose levels12 and tissue hypoperfusion.16-19 
Measurement mistakes may lead to unnecessary procedures regarding 
insulin doses and increase the risk of severe or prolonged hypoglyce-
mia and its complications such as seizures, coma, arrhythmia and ir-
reversible cerebral damage.12 
OBJECTIVE
This study aimed to compare capillary (Cgluc-strip) and arterial 
(Agluc-strip) blood glucose levels measured by a glucometer in critically 
ill patients, with their arterial blood glucose levels measured by means of 
colorimetry (Agluc-lab), which was considered to be the gold standard. 
Subgroups of individuals either using noradrenalin or presenting tissue 
hypoperfusion were also analyzed. 
In addition, we also assessed the agreement with blood glucose lev-
els measured through the central venous line by means of colorimetry 
(Vgluc-lab). Secondarily, we sought to determine whether the measure-
ment method had any impact on the glucose level control procedures, 
based on a strict and well-established protocol. 
METHODS
Type of study
This was a cross-sectional study carried out at a tertiary public institu-
tion. It was conducted in the intensive care unit of the Discipline of Anes-
thesiology, Pain and Intensive Care of Hospital São Paulo, Universidade 
Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM). 
The research project had previously been analyzed and approved by the 
institution’s Ethics Committee. A free and informed consent statement 
was signed by all participating patients or their legal representatives.
Sample
Forty patients were included based on the following inclusion crite-
ria: age ≥ 18 years; presence of arterial and central venous lines; inten-
sive glycemic control in accordance with the institution’s protocol and 
a signed informed consent statement. Patients with either diabetes or 
hemodynamic instability that was not solely related to sepsis were ex-
cluded. 
Patients with two different profiles were recruited for the study. The 
first type consisted of patients in septic shock, on any dose of noradren-
alin. The second type consisted of patients with no confirmed or pre-
sumed infection, who did not require noradrenalin for any reason what-
soever. Septic shock was defined in accordance with the 1992 consensus 
conference, as described elsewhere.20 In assessing tissue perfusion, hy-
poperfusion was defined as the presence of oxygen central venous satu-
ration (ScvO2) lower than 70 mmHg and lactate higher than 20 mg/l.
Procedures
A single set of tests was obtained per patient: Cgluc-strip, Agluc-
strip, Vgluc-lab, Agluc-lab, arterial lactate and arterial and central ve-
nous blood gas determinations. Serum sodium, potassium, creatinine 
and bilirubin levels were obtained through the unit’s routine tests. Arte-
rial and central venous lines were used for sample collection. The cath-
eter lumen was washed with 10 ml of distilled water, followed by aspi-
ration of 5 ml of blood to be discarded before the sample collection. 
The samples were immediately send to the laboratory and processed by 
a technician who was unaware of the sample origin. The Agluc-lab and 
Vgluc-lab measurements were each made using 3 ml of sample in tubes 
containing ethylenediaminetetraacetic acid (EDTA). This was done in 
the Olympus Au640e device, with hexokinase G-6-pyruvate dehydro-
genase A (G-6-PDHA) reagent. Arterial and central venous blood gas 
and arterial lactate were determined by means of a microtechnique in 
the ABL 700 Series Radiometer® (Copenhagen, Denmark), on samples 
of 1 ml each in heparinized syringes. For Cgluc-strip, blood from the 
finger pad lanced with a 26G needle was used. Analysis was performed 
by the investigator immediately after sampling. The glucometer avail-
able at the institution was the Medisense FreeStyle Optium® (Abbott 
Laboratories, United States). The glucometer manufacturer’s manual 
specifies hematocrit as the only interfering variable, ranging between 
15% and 65%.
The tests and clinical data were stored on a standardized case report 
form for each patient. Intensive glucose control was carried out in ac-
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cordance with the institution’s protocol, which uses Cgluc-strip on a 
routine basis. The other blood glucose levels did not interfere with the 
intensive glucose control procedures that were used by the physician on 
call, except if Agluc-lab was lower than 40 mg/dl. 
The Acute Physiology and Chronic Health Evaluation II (APACHE 
II) on admission to the unit and the Sequential Organ Failure Assess-
ment (SOFA) on the sample collection day were calculated. There was 
no deadline for patient inclusion after the first organ dysfunction.
Analysis of results was performed on the full data set and also con-
sidering the subgroups defined above, i.e. patients with and without 
septic shock. Thus, patients in septic shock (on noradrenalin) were com-
pared with those who were stable from a hemodynamic point of view 
(not using noradrenalin), regardless of the tissue perfusion, with the aim 
of assessing the possible effects of the vasoconstrictor on the agreement 
of the Cgluc-strip. Likewise, whether or not these patients were on no-
radrenalin, they were assessed in relation to the signs of tissue hypoper-
fusion (ScvO2 and lactate).
Assessment of the conformity of clinical management using the re-
sults provided by the different methods was based on the institution’s 
protocol, using the latest capillary glucose level for comparison. This 
analysis was performed in a blinded manner.
Statistical methods
The sample size calculation was performed based on the correlation 
between Agluc-lab and Cgluc-strip, taking the null hypothesis to be ab-
sence of correlation, with r = 0.55 and, as an alternative hypothesis, the 
existence of a correlation with r = 0.80. Considering a significance level 
of 0.05 and power of 0.80 in a two-sided test, a sample of 38 patients 
would be needed.
Descriptive analysis of the population’s characteristics was carried 
out. The variables analyzed were subjected to the Shapiro-Wilk normal-
ity test. Results relating to continuous variables were expressed as means 
and standard deviations. Categorical variables were expressed as per-
centages and were subjected to the chi-square test. The results were con-
sidered statistically significant if P < 0.05. 
Pearson’s coefficient was used to determine the correlation between 
the different measurements of glucose levels in relation to Agluc-lab, 
which was considered to be the gold standard.21,22 This correlation anal-
ysis between methods was based on standards established by the Clinical 
and Laboratory Standards Institute (CLSI). These standards state that 
two different methods for glucose level evaluation are equivalent if Pear-
son’s coefficient is greater than 0.9751.21,22
The agreement between the methods was established by means of 
the Bland and Altman test.23 The “bias” was defined as the mean differ-
ence between two measurements made by different methods; accuracy 
as the standard deviation of the “bias”; and the limit of agreement as two 
standard deviations (95%) of the “bias”. Furthermore, the CLSI defines 
that 95% of the results from non-laboratory measurements of glucose 
levels need to differ by less than ± 15 mg/dl in relation to the laboratory 
measurement, if the latter is < 75 mg/dl. If the laboratory measurement 
is ≥ 75 mg/dl, the variation needs to be less than ± 20% of the labora-
tory value.21,22 
The Epi-Info and GraphPad Prism 5 statistical software were used.
RESULTS
Forty non-consecutive patients were included in the study between 
October 2006 and April 2007. Of these, 26 (65.0%) were male. The 
reasons for the patients’ hospital admission were clinical disease in 12 
cases (30.0%), emergency surgery in 15 (37.5%) and elective surgery in 
13 (32.5%). The mean length of hospital stay at the time of inclusion 
was 3.7 ± 6.2 days. The mean age, APACHE II and SOFA were respec-
tively: 55.3 ± 17.7; 15.5 ± 8.6; and 7.2 ± 4.3.
Noradrenalin was used for 24 patients and of these, 11 (45.0%) 
presented tissue perfusion abnormalities. Among the other 16 patients 
(without noradrenalin), only four (25.0%) presented tissue perfusion 
abnormalities (P = 0.158). Only one patient had mean arterial pressure 
(MAP) lower than 65 mmHg at the sample collection time. Among 
the 15 patients with tissue hypoperfusion, six had ScvO2 abnormali-
ties (mean = 56.4 ± 18.4) and nine had lactate abnormalities (mean = 
49.5 ± 22.8). None of the patients had concomitant ScvO2 and lactate 
alteration.
With regard to possible hematocrit interference with glucose lev-
el determinations by means of glucometry, the mean hematocrit level 
was 26.5% ± 4.3, with a minimum value of 17.0% and maximum of 
36.0%, in agreement with the limits specified by the device manufac-
turer.
The mean glucose values were: Agluc-lab = 140.8 mg/dl ± 51.9; 
Cgluc-strip = 150.7 ± 55.8 mg/dl; Agluc-strip = 147.5 mg/dl ± 56.1; 
Vgluc-lab = 145.0 mg/dl ± 53.2. In Pearson’s correlation analysis, none 
of the blood glucose level determinations was satisfactory, in relation 
to Agluc-lab (Table 1). The worst correlation was with Cgluc-strip 
(r = 0.8289; P < 0.0001) (Figure 1-A). Bland and Altman’s method (Ta-
ble 2) showed bias between Agluc-lab and Cgluc-strip equal to -9.8 mg/
dl ± 31.7 (-72.12 to 52.37) (Figure 1-B). Cgluc-strip was higher than 
Agluc-lab in 26 patients (65.0%), with a mean variation of 25.7 mg/dl, 
while in the other 14 patients (35.0%), it was less than Agluc-lab, with a 
mean variation of 19.6 mg/dl. Analyzing the data according to the CLSI 
recommendations with regard to the acceptable percentage variation, 
only two Agluc-lab values lower than 75 mg/dl were found, which both 
had Cgluc-strip values within the acceptable limits of variation (± 15 
mg/dl). However, when Agluc-lab was greater than or equal to 75 mg/
dl (38 cases), Cgluc-strip was outside of the acceptable limits (± 20% of 
the Agluc-lab value) in nine cases (23.6%) (Table 3). In these nine cases, 
eight Cgluc-strip values overestimated the Agluc-lab. When Agluc-lab 
was higher than 150 mg/dl, such variation occurred in 28.5%.
Table 1. Correlation between arterial blood glucose levels measured by 
colorimetry and other methods
Method
Group
Full sample 
(n = 40)
Noradrenalin use Tissue perfusion
Yes (n = 24) No (n = 16)
Abnormal 
(n = 15)
Normal 
(n = 25)
Cgluc-strip 0.8289* 0.8246* 0.9612* 0.7983† 0.8951*
Agluc-strip 0.9400* 0.9526* 0.9175* 0.9541* 0.9454*
Vgluc-lab 0.8549* 0.9272* 0.6835‡ 0.9253* 0.7918*
Cgluc-strip: capillary blood glucose levels measured by glucometry; Agluc-strip: arterial blood glucose levels 
measured by glucometry; Vgluc-lab: central venous blood glucose levels measured by colorimetry. Pearson’s 
correlation. *P < 0.0001; †P = 0.0004; ‡P = 0.035.
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Figure 1. Pearson’s coefficient (1-A) and Bland and Altman’s test (1-B) between capillary blood glucose levels measured by glucometry (Cgluc-strip) 
and arterial blood glucose levels measured by colorimetry (Agluc-lab). Figure 1-A: r = 0.8289. Figure 1-B: bias = -9.87 ± 31.76 (-72.12 to +52.37). Full 
sample (n = 40). Blood glucose in mg/dl.
Although unsatisfactory, Agluc-strip showed the best correlation 
with Agluc-lab (r = 0.9400; P < 0.0001) (Figure 2-A), with agreement 
in Bland and Altman’s test equal to -6.75 mg/dl ± 19.07 (-44.13 to 
30.63) (Figure 2-B). Significant variation (CLSI criteria) was found in 
just three cases (7.5%), all with Agluc-strip higher than Agluc-lab. All 
patients had Agluc-lab greater than 75 mg/dl. In relation to Vgluc-lab, 
it presented r = 0.8549 (P < 0.0001) (Figure 3-A) and bias of -4.2 mg/
dl ± 28.37 (-59.81 to 51.41) (Figure 3-B).
For Cgluc-strip, analysis of the noradrenalin subgroup showed that 
a significant percentage of measurements were outside of the acceptable 
limits of variation: 36.4% of the patients on noradrenalin and 6.3% of 
the patients not receiving noradrenalin (P = 0.03). On the other hand, 
there was no significant difference regarding tissue perfusion (35.7% 
and 16.7% in the subgroups with and without hypoperfusion, respec-
tively; P = 0.17). With regard to the other methods, no significant dif-
ference was found in any of the subgroups. For these subgroups, the 
Table 3. Distribution of patients according to the Clinical and Laboratory Standard Institute (CLSI) recommendations regarding the acceptable percentage 
variation
Group
Method
Cgluc-strip Agluc-strip Vgluc-lab
≥ ± 20%† < ± 20%† ≥ ± 20%† < ± 20%† ≥ ± 20%† < ± 20%†
Full sample (n = 38)* 9 (23.4) 29 (76.6) 3 (7.9) 35 (92.1) 6 (15.7) 32 (84.3)
Noradrenalin use
Yes (n = 22) 8 (36.4) 14 (63.6) 2 (9.1) 20 (90.9) 2 (9.1) 20 (90.9)
No (n = 16) 1 (6.3) 15 (93.8) 1 (6.3) 15 (93.8) 4 (25) 12 (75)
P 0.03 0.62 0.18
Tissue perfusion  
Abnormal (n = 14) 5 (35.7%) 9 (64.3) 2 (14.3) 12 (85.7) 2 (14.3) 12 (85.7)
Normal (n = 24) 4 (16.7%) 20 (83.3) 1 (95.8) 23 (4.2) 4 (16,7) 20 (83.3)
P 0.17 0.30 0.60
*Excluding two patients with Agluc-lab < 75 mg/dl. Cgluc-strip: capillary blood glucose levels measured by glucometry; Agluc-strip: arterial blood glucose levels measured by glucometry; Vgluc-lab: central venous blood glucose 
levels measured by colorimetry. †percentage of variation in relation to Agluc-lab. Chi-square test. Number of patients (%).
Table 2. Agreement between arterial blood glucose levels measured by colorimetry and other methods
Group
Method
Cgluc-strip Agluc-strip Vgluc-lab
Full sample (n = 40) -9.87 ± 31.76 (-72.12-52.37) -6.75 ± 19.07 (-44.13-30.63) -4.20 ± 28.37 (-59.81-51.41)
Noradrenalin use
Yes (n = 24) -13.91 ± 37.91 (-88.23-60.40) -11.20 ± 20.02 (-50.46-28.04) 4.08 ± 22.79 (-40.58-48.75)
No (n = 16) -3.81 ± 18.78 (-40.63-33.01) -0.06 ± 15.85 (-31.13-31.01) -16.62 ± 31.97 (-79.30-46.05)
Tissue perfusion
Abnormal (n = 15) -7.24 ± 20.76 (-47.94-33.46) -1.60 ± 15.36 (-31.71-28.51) -6.08 ± 31.20 (-67.23-55.07)
Normal (n = 25) -14.26 ± 45.14 (-102.74-74.21) -15.33 ± 21.96 (-58.39-27.72) -1.06 ± 23.60 (-47.32-45.19)
Cgluc-strip: capillary blood glucose levels measured by glucometry; Agluc-strip: blood glucose levels measured by glucometry; Vgluc-lab: central venous blood glucose levels measured by colorimetry. Bland and Altman’s test: bias 
± standard deviation (limits of agreement). Blood glucose in mg/dl.
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results from Pearson’s test and Bland and Altman’s test were similar to 
those for the full population, thereby showing no specific features (Ta-
bles 1 and 2). 
Regarding clinical management, all of the methods led to some form 
of change in relation to Agluc-lab. The greatest change occurred with Cg-
luc-strip (n = 10.25%). For Agluc-strip, there was a management change 
for six patients (15.0%) and for Vgluc-lab, for nine patients (22.5%). 
These data and those for the subgroups are shown in Table 4.
DISCUSSION
The results from this study suggest that Cgluc-strip should be avoid-
ed in an intensive care setting and that, when used, its results should be 
carefully interpreted. Its results could lead to improper management, 
thereby exposing the patients to a larger and prolonged number of hy-
poglycemic events.16-18,24,25 
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Figure 2. Pearson’s coefficient (2-A) and Bland and Altman’s test (2-B) between arterial blood glucose levels measured by glucometry (Agluc-strip) and 
arterial blood glucose levels measured by colorimetry (Agluc-lab). Figure 2-A: r = 0.9400. Figure 2-B: bias = -6.75 ± 19.07 (-44.13 to +30.63). Full 
sample (n = 40). Blood glucose in mg/dl.
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Figure 3. Pearson’s coefficient (3-A) and Bland and Altman’s test (3-B) between central venous blood glucose levels measured by colorimetry (Vgluc-lab) 
and arterial blood glucose levels measured by colorimetry (Agluc-lab). Figure 3-A: r = 0.8549. Figure 3-B: bias = -4.20 ± 28.37 (-59.81 to +51.41). Full 
sample (n = 40). Blood glucose in mg/dl.
In studies conducted by van den Berghe et al., glucose control was 
carried out by means of Agluc-lab. In the first study8 on surgical pa-
tients, there were greater numbers of hypoglycemic events in the strict 
control group, in relation to the standard therapy group, from 0.8% to 
5.1%. In the second study,7 this increase among clinical patients ranged 
from 3.1% to 18.7%. Thus, even with reliable glycemic measurements 
(Agluc-lab), patients undergoing intensive glucose control are more 
susceptible to hypoglycemic events and to related morbid events.5 The 
present study emphasizes that the use of Cgluc-strip may compromise 
accurate analysis on glucose values and increase the chances of hypogly-
cemic events. Moreover, in 20.0% of the cases (n = 8), Cgluc-strip over-
estimated the true glucose values. Cgluc-strip tended towards overesti-
mating Agluc-lab, particularly in relation to extreme glucose values, and 
this had already been described in a previous study conducted by Kanji 
et al.12 These authors showed that, in hypoglycemic patients, variation 
beyond the acceptable limits occurred between Cgluc-strip and the ref-
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erence method in 73.7%. Most of the time, Cgluc-strip overestimated 
the reference values, thereby delaying the diagnosis and hypoglycemia 
management. Such analysis was not performed in the present study, 
since there were only two cases of Agluc-lab < 70 mg/dl. 
This study does not allow us to state whether the Cgluc-strip mea-
surement error can be ascribed to the glucometer used, since only one 
type of device was used. Studies in the literature, using different devices, 
have shown significant Cgluc-strip errors and have suggested that such 
measurements should not be used in cases of critically ill patients.12,16-
18,25 This downplays the idea that the error in glucose value measurement 
using a glucometer could possibly be related to the type of device used. 
Laboratory interference variables were eliminated. According to the lit-
erature, pH and pO2 values are not considered to be factors of relevance 
regarding interference.13,14 However, extreme hematocrit values can sig-
nificantly interfere with Cgluc-strip measurements.15 Nevertheless, he-
matocrit values have been found to be within the limits permitted, for 
the device used, in all patients.26 Another factor giving rise to possible 
interference with Cgluc-strip would be the presence of edema in the ex-
tremities, which is a subjective clinical finding that was not analyzed at 
the time of sample collection in the present study. Kanji et al.12 assessed 
this matter and showed that the edema caused no error additional to 
what would be expected from this method. 
The worst accuracy of Cgluc-strip, according to the CLSI criteria, 
was found in relation to patients on noradrenalin. In this subgroup, Cg-
luc-strip predominantly overestimated Agluc-lab, which places these pa-
tients at greater risk of hypoglycemia and more prolonged events, prob-
ably because they would receive a late diagnosis. This could have an 
impact on the evolution of and prognosis for critically ill patients, al-
though so far there is no definitive evidence in the literature to suggest 
that accidental hypoglycemia would have an impact on mortality.27 No-
radrenalin use has been found by several authors to have an influence 
on Cgluc-strip. In a retrospective study on 2,272 patients, Vriesendorp 
et al.28 assessed the risk factors for hypoglycemia using Agluc-lab and 
found that the use of a vasopressor was an important issue. They reached 
the conclusion that regardless of the glucose measurement method, pa-
tients with greater severity of illness were more subject to hypoglycemic 
events. In a multivariate analysis on situations that compromised the 
accuracy of Cgluc-strip, Critchell el al.19 showed that only the use of a 
vasopressor was significant. Kulkarni et al.17 analyzed 493 Cgluc-strip 
measurements, 75 of which from hemodynamically unstable patients, 
and showed that only in this group was there unacceptable accuracy. 
Another study, by Sylvain et al.,18 analyzed Cgluc-strip in 38 hemody-
namically unstable patients, among whom 70% were on noradrenalin. 
The mean difference in relation to the reference method was 77 mg/dl. 
Atkin et al.16 also assessed unstable patients and found that Cgluc-strip 
presented acceptable agreement only in 36% of the measurements. 
The present study also sought to correlate the accuracy of Cgluc-
strip in relation to patients with signs of hypoperfusion, and this anal-
ysis differentiates this study from others in the literature. However, al-
though the percentage of results above the acceptable limits was greater 
in the hypoperfusion group (35.7%), there was no significant difference 
in relation to the patients without any signs of hypoperfusion (16.7%). 
Such a difference would be expected, since there was a significant differ-
ence in relation to the group receiving noradrenalin, including similar 
percentages (36.4%). There may be many causes for such findings. The 
absence of statistical significance could perhaps be ascribed to the small 
size of the sample studied. Moreover, the methods chosen for hypoper-
fusion assessment (ScvO2 and lactate) were deficient, since they were less 
specific than the need for a vasopressor. 
Agluc-strip was the method that was shown to be most represen-
tative of Agluc-lab. This is an important finding because most of the 
patients on noradrenaline had arterial lines available for sampling. As 
pointed out earlier, this was the group presenting the worst accuracy of 
Cgluc-strip, according to the CLSI criteria. Thus, in this group, arterial 
blood should be used for sampling whenever arterial lines are available, 
in order to minimize the risk of hypoglycemia. 
Blood samples processed in a glucometer, except for capillary sam-
ples, have proven to be reliable in other studies.12,16,18 This suggests that 
the measurement error is predominantly related to the type of sample 
(capillary blood) rather than solely to the use of glucometers. Nonethe-
less, although Agluc-strip is, on a comparative basis, better than the lab-
oratory method, its variation limits according to Bland and Altman’s test 
(-6.75 mg/dl ± 19.07) can be considered unacceptable from a medical 
point of view, particularly for patients at the lower limit of glucose levels 
(less than 70 mg/dl). Wide limits of variation were also found for Vgluc-
lab (-4.20 mg/dl ± 28.37) and Cgluc-strip (-9.87 mg/dl ± 31.76), thus 
making its representativeness in relation to Agluc-lab questionable. This 
sounds odd, considering that both samples were processed using the lab-
oratory method and expressed systemic characteristics. One possible ex-
planation for this would be that some venous blood samples were con-
taminated by glucose solutions that were being administered through 
the sample collection route, although the collection technique used was 
appropriate for avoiding such occurrences. 
Table 4. Conformity in clinical management based on the institution’s 
protocol, using results provided by different methods in relation to the 
latest capillary glucose level 
Cgluc strip Agluc-strip Vgluc-lab
Full sample (n = 40)
Management unchanged 30 (75.0) 34 (85.0) 31 (77.5)
Management changed 10 (25.0) 6 (15.0) 9 (22.5)
Noradrenalin use
Yes (n = 24)
Management unchanged 17 (71.0) 21 (87.5) 21 (87.5)
Management changed 7 (29.0) 3 (12.5) 3 (12.5)
No (n = 16)
Management unchanged 13 (81.5) 13 (81.5) 10 (62.5)
Management changed 3 (18.5) 3 (18.5) 6 (37.5)
P 0.7110 0.6678 0.1198
Tissue perfusion
Altered (n = 15)
Management unchanged 18 (72.0) 21 (84.0) 18 (72.0)
Management changed 7 (28.0) 4 (16.0) 7 (28.0)
Normal (n = 25)
Management unchanged 12 (80.0) 13 (86.0) 13 (86.0)
Management changed 3 (20.0) 2 (14.0) 2 (14.0)
P 0.7148 1.0000 0.4401
Cgluc-strip: capillary blood glucose levels measured by glucometry; Agluc-strip: arterial blood glucose levels 
measured by glucometry; Vgluc-lab: central venous blood glucose levels measured by colorimetry. Chi-square 
test. Number of patients (%).
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This study has some limitations. First, patients were included on a 
nonconsecutive basis and, therefore, selection bias cannot be ruled out. 
Second, in the laboratory samples, glucose could have been used by red 
blood cells, thereby contributing towards the relative higher levels in the 
strip samples. However, this seems quite unlikely because the samples 
were immediately sent to the laboratory for processing. Third, the strip 
samples were not analyzed in a blinded fashion. However, because the 
analysis was performed by means of glucometry, the investigator was 
unable to interfere in the results. 
CONCLUSION
The results suggest that the use of Cgluc-strip in intensive care must 
be avoided, particularly if noradrenalin is being used. Predominantly, 
this method overestimates blood glucose levels, which implies proce-
dural errors and exposes patients to more frequent and prolonged hy-
poglycemic events. Agluc-strip is the most representative method and it 
should be adopted as a technique for replacing the laboratory method 
whenever arterial lines are available. In all other patients, Cgluc-strip 
values should be routinely checked against laboratory values, particu-
larly when the levels are at the lower limit of normality, in order to rule 
out hypoglycemia. 
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